For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the pulmonary or respiratory drug delivery industry, and what is its expected CAGR?
The pulmonary or respiratory drug delivery market size has grown strongly in recent years. It will grow from $69.83 billion in 2024 to $76.38 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing prevalence of asthma, rising adoption of advanced inhalation devices, growth in healthcare expenditure globally, rising awareness of respiratory diseases, and rising incidence of allergic conditions.
The pulmonary or respiratory drug delivery market size is expected to see strong growth in the next few years. It will grow to $107.85 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, rising prevalence of chronic respiratory diseases, growing emphasis on telemedicine, increasing investments in healthcare infrastructure, and growth in e-commerce for pharmaceutical products. Major trends in the forecast period include advancements in particle engineering, development of advanced nebulizers, development of liposomal formulations, advancements in computational fluid dynamics, development of smart inhalers.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
What external factors are influencing the pulmonary or respiratory drug delivery market’s growth momentum?
The increasing prevalence of pneumonia is expected to propel the growth of the pulmonary or respiratory drug delivery market going forward. Pneumonia is a lung infection that causes inflammation of the air sacs, which may fill with fluid or pus, leading to symptoms like cough, fever, and difficulty breathing. The increasing prevalence of pneumonia such as aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the rise of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery helps pneumonia patients by directly targeting the lungs with medications, such as antibiotics, bronchodilators, or anti-inflammatory agents, enabling faster and more effective treatment to alleviate symptoms, reduce inflammation, clear infections, and improve respiratory function, ultimately enhancing recovery and preventing complications. For instance, in November 2023, according to the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, pneumonia cases in Kenya rose significantly, reaching 793,864 in 2022/2023. Therefore, the increasing prevalence of pneumonia drives the pulmonary or respiratory drug delivery market.
What are the major market segments driving the growth of the pulmonary or respiratory drug delivery industry?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
View The Full Market Report:
What are the key trends shaping the pulmonary or respiratory drug delivery market in the forecast period?
Major companies operating in the pulmonary or respiratory drug delivery market are focusing on technological advancements such as complex drug delivery systems that enhance treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, improving drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines and Kindeva Drug Delivery L.P., a US-based company that offers drug delivery launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US-based government agency. This is the first generic version of AstraZeneca’s Symbicort and a metered-dose inhaler that combines budesonide and formoterol for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.
Who are the key market players contributing to the growth of the pulmonary or respiratory drug delivery industry?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Which regions are leading the growth of the pulmonary or respiratory drug delivery market globally?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Pulmonary Or Respiratory Drug Delivery Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939
Need Customized Data On Pulmonary Or Respiratory Drug Delivery Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
